HZB coordinates European collaboration to develop active agents against Corona
The MX team at BESSY II specialises in analysing protein structures. This can also accelerate the development of drugs against COVID-19. © HZB
X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. Now, a team at HZB with partners from Austria and the Czech Republic has set up the NECESSITY project to investigate more than 8000 compounds in a high-throughput procedure and develop active agents against COVID-19.
The COVID-19 pandemic is far from over. Despite the rapid development of vaccines, it is not possible, for various reasons, to give everyone lasting protection through vaccination quickly enough. But so far, there are hardly any effective drugs for patients severely affected by COVID-19. Therapy is mainly limited to the administration of steroid drugs to control the immune reaction and artificial respiration.
Researchers around HZB-scientist Dr. Christian Feiler have initiated a three-party European research study termed NECESSITY, led by project partner Prof. Dr. Klaus Scheffzek (Med. University Innsbruck, Austria). Their goal is to investigate detailed interactions between Sars-CoV-2 proteins and chemical compounds developed and provided by Dr. Vladimír Kryštof (Palacký University Olomouc, the Czech Republic), using structural and biochemical approaches. X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. This research is funded by the Austrian Science Fund (FWF), the German Research Foundation (DFG), and the Czech Science Foundation (GACR).
At the light source BESSY II, which is operated by HZB, the structural analysis of macromolecules provides a fantastic tool to accelerate the development of effective substances against the SARS-CoV2 virus. The three-dimensional structure of the so-called viral main protease was determined at BESSY II for the first time at the beginning of 2020. This enzyme is indispensable for virus replication. However, it is not sufficient to investigate this one target, which is why several viral target proteins are being addressed in the NECESSITY project. The consortium will explore more than 8000 compounds at the MX-beamlines of BESSY II in a high-throughput procedure and identify substances from them that could dock to the main protease of SARS-CoV-2 or other target proteins. These drug-like candidates originate from a unique library generated and collected by Dr. Vladimír Kryštof, Palacký University Olomouc. All compounds are either already approved for the treatment of other diseases or are in various clinical phases. If hits were to come out of this, it would be possible to develop drugs against COVID-19 remarkably quickly. Prof. Dr. Klaus Scheffzek and his team at the Medical University in Innsbruck can investigate the hit compounds in detail using biophysical methods and initiate the first virological studies. Prof. Dr. Christian Drosten, Director of the Institute of Virology at Charité Berlin, and other experts are also on board as advisors and partners.
"In the NECESSITY project, we bring together expertise from different fields," says Feiler. "Together, we have planned a very efficient interdisciplinary workflow to identify antiviral substances that can be used as effective drugs against COVID-19 and beyond as quickly as possible."
The project is funded by the German Research Foundation and the corresponding funding organizations in Austria and the Czech Republic for 36 months with almost 800,000 Euros.
- Green hydrogen: A cage structured material transforms into a performant catalystClathrates are characterised by a complex cage structure that provides space for guest ions too. Now, for the first time, a team has investigated the suitability of clathrates as catalysts for electrolytic hydrogen production with impressive results: the clathrate sample was even more efficient and robust than currently used nickel-based catalysts. They also found a reason for this enhanced performance. Measurements at BESSY II showed that the clathrates undergo structural changes during the catalytic reaction: the three-dimensional cage structure decays into ultra-thin nanosheets that allow maximum contact with active catalytic centres. The study has been published in the journal ‘Angewandte Chemie’.
- Solar cells on moon glass for a future base on the moonFuture settlements on the moon will need energy, which could be supplied by photovoltaics. However, launching material into space is expensive – transporting one kilogram to the moon costs one million euros. But there are also resources on the moon that can be used. A research team led by Dr. Felix Lang of the University of Potsdam and Dr. Stefan Linke of the Technical University of Berlin have now produced the required glass from ‘moon dust’ (regolith) and coated it with perovskite. This could save up to 99 percent of the weight needed to produce PV modules on the moon. The team tested the radiation tolerance of the solar cells at the proton accelerator of the HZB.
- Optical innovations for solar modules - which are the most promising?In 2023, photovoltaic systems generated more than 5% of the world’s electrical energy and the installed capacity doubles every two to three years. Optical technologies can further increase the efficiency of solar modules and open up new applications, such as coloured solar modules for facades. Now, 27 experts provide a comprehensive overview of the state of research and assess the most promising innovations. The report, which is also of interest to stakeholders in funding and science management, was coordinated by HZB scientists Prof. Christiane Becker and Dr. Klaus Jäger.